Skip to main
  1. Stocks
  2. OmniAb Inc
  3. Forecast
OABI

OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb Inc (OABI) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OmniAb is well positioned because its Biological Intelligence platform, proprietary transgenic animal models, and deep immune-repertoire datasets create a differentiated discovery engine that helps partners identify optimized antibodies and other binders faster than conventional approaches. Its outlook is further supported by a growing royalty aggregation model with a steady cadence of milestone revenue, potential milestones of more than $3B, a 425-program portfolio with 98% downstream economics, and a newly disclosed $370M Lilly collaboration that validates the platform. Management also expects xPloration revenue of $2M–$3M in 2026, with doubling in 2027 and again in 2028, while raised 2026 year-end cash guidance of $49M–$53M reinforces financial flexibility to fund expansion.

Bears say

OmniAb is exposed to a business model where most value depends on downstream milestones and royalties, so any delay or failure in partner asset approvals would directly weaken valuation and cash flow visibility. Near-term caution in biopharma capital spending could slow program adds, while a surge in AI-driven sequence design may reduce demand for animal-based discovery methods and leave its platform vulnerable to commoditization or patent pressure. With revenue tied to partner growth and deal terms, even modest setbacks in adoption or competitive differentiation could materially impair future royalties and long-term attractiveness.

OmniAb Inc (OABI) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.

OmniAb Inc (OABI) Analyst Forecast & Price Prediction

Get the latest OmniAb Inc (OABI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OmniAb Inc (OABI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OmniAb Inc (OABI) Forecast

Analysts have given OmniAb Inc (OABI) a Strong Buy based on their latest research and market trends.

According to 3 analysts, OmniAb Inc (OABI) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OmniAb Inc (OABI)


OmniAb Inc (OABI) Analyst Forecast & Price Prediction

Get the latest OmniAb Inc (OABI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OmniAb Inc (OABI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OABI stock data and trends